Wittchen H-U, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, Olesen J, Allgulander C, Alonso J, Faravelli C. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655–79.
Article CAS PubMed Google Scholar
Paparrigopoulos T, Tzavara C, Theleritis C, Psarros C, Soldatos C, Tountas Y. Insomnia and its correlates in a representative sample of the Greek population. BMC Public Health. 2010;10:531.
Article PubMed PubMed Central Google Scholar
Voitsidis P, Gliatas I, Bairachtari V, Papadopoulou K, Papageorgiou G, Parlapani E, Syngelakis M, Holeva V, Diakogiannis I. Insomnia during the COVID-19 pandemic in a Greek population. Psychiatry Res. 2020;289: 113076.
Article CAS PubMed PubMed Central Google Scholar
Riemann D, Baglioni C, Bassetti C, Bjorvatn B, DolencGroselj L, Ellis JG, Espie CA, Garcia-Borreguero D, Gjerstad M, Gonçalves M, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26(6):675–700.
De Crescenzo F, D’Alò GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, Kurtulmus A, Tomlinson A, Mitrova Z, Foti F, et al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet. 2022;400(10347):170–84.
Schifano F, Chiappini S, Corkery JM, Guirguis A. An insight into Z-drug abuse and dependence: an examination of reports to the european medicines agency database of suspected adverse drug reactions. Int J Neuropsychopharmacol. 2019;22(4):270–7.
Article CAS PubMed PubMed Central Google Scholar
Buth S, Holzbach R, Martens M-S, Neumann-Runde E, Meiners O, Verthein U. Problematic medication with Benzodiazepines, “Z-drugs”, and opioid analgesics. Dtsch Arztebl Int. 2019;116(37):607–14.
PubMed PubMed Central Google Scholar
Landolt S, Rosemann T, Blozik E, Brüngger B, Huber CA. Benzodiazepine and Z-drug use in Switzerland: prevalence, prescription patterns and association with adverse healthcare outcomes. Neuropsychiatr Dis Treat. 2021;17:1021–34.
Article PubMed PubMed Central Google Scholar
Agarwal SD, Landon BE. Patterns in outpatient benzodiazepine prescribing in the United States. JAMA Netw Open. 2019;2(1):e187399–e187399.
Article PubMed PubMed Central Google Scholar
Cadogan CA, Ryan C, Cahir C, Bradley CP, Bennett K. Benzodiazepine and Z-drug prescribing in Ireland: analysis of national prescribing trends from 2005 to 2015. Br J Clin Pharmacol. 2018;84(6):1354–63.
Article CAS PubMed PubMed Central Google Scholar
Calem M, Bisla J, Begum A, Dewey M, Bebbington PE, Brugha T, Cooper C, Jenkins R, Lindesay J, McManus S. Increased prevalence of insomnia and changes in hypnotics use in England over 15 years: analysis of the 1993, 2000, and 2007 national psychiatric morbidity surveys. Sleep. 2012;35(3):377–84.
Article PubMed PubMed Central Google Scholar
Bakirtzis C, Grigoriadou E, Boziki MK, Kesidou E, Siafis S, Moysiadis T, Tsakona D, Thireos E, Nikolaidis I, Pourzitaki C, et al. The administrative prevalence of multiple sclerosis in Greece on the basis of a nationwide prescription database. Front Neurol. 2020;11:1012.
Article PubMed PubMed Central Google Scholar
ELSTAT: Estimated population / 2021. https://www.statistics.gr/en/statistics/-/publication/SPO18/-. In.; 2021.
R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/.
Morin CM, Vézina-Im LA, Ivers H, Micoulaud-Franchi JA, Philip P, Lamy M, Savard J. Prevalent, incident, and persistent insomnia in a population-based cohort tested before (2018) and during the first-wave of COVID-19 pandemic (2020). Sleep. 2022;45(1):zsab258.
Brandt J, Leong C. Benzodiazepines and Z-drugs: an updated review of major adverse outcomes reported on in epidemiologic research. Drugs R&D. 2017;17(4):493–507.
Patel D, Steinberg J, Patel P. Insomnia in the elderly: a review. J Clin Sleep Med. 2018;14(6):1017–24.
Article PubMed PubMed Central Google Scholar
Baglioni C, Altena E, Bjorvatn B, Blom K, Bothelius K, Devoto A, Espie CA, Frase L, Gavriloff D, Tuuliki H, et al. The European academy for cognitive behavioural therapy for insomnia: an initiative of the European insomnia network to promote implementation and dissemination of treatment. J Sleep Res. 2020;29(2): e12967.
Samara MT. What is the right drug for insomnia disorder? The Lancet. 2022;400(10347):139–41.
Samara MT, Huhn M, Chiocchia V, Schneider-Thoma J, Wiegand M, Salanti G, Leucht S. Efficacy, acceptability, and tolerability of all available treatments for insomnia in the elderly: a systematic review and network meta-analysis. Acta Psychiatr Scand. 2020;142(1):6–17.
Article CAS PubMed Google Scholar
Sirdifield C, Chipchase SY, Owen S, Siriwardena AN. A systematic review and meta-synthesis of patients’ experiences and perceptions of seeking and using benzodiazepines and Z-drugs: towards safer prescribing. Patient - Patient-Centered Outcomes Res. 2017;10(1):1–15.
Gentile G, Lapeyre-Mestre M, Micallef J. Combatting the misuse of benzodiazepines and related Z drugs in French general practice: a clinical review. BJGP Open. 2020;4(1):bjgpopen20X101014.
Article PubMed PubMed Central Google Scholar
Caillet P, Rousselet M, Gerardin M, Jolliet P, Victorri-Vigneau C. Prevalence of zolpidem use in France halved after secure prescription pads implementation in 2017: A SNDS database nested cohort study. PLoS ONE. 2020;15(2):e0228495–e0228495.
Article CAS PubMed PubMed Central Google Scholar
Istvan M, Caillet P, Rousselet M, Guerlais M, Laforgue E-J, Gérardin M, Jolliet P, Feuillet F, Victorri-Vigneau C. Change in the regulatory framework for zolpidem: What is the impact on the landscape of the prescription of sedative medications? The French national ZORRO study. Br J Clin Pharmacol. 2021;87(8):3310–9.
Article CAS PubMed Google Scholar
Laforgue EJ, Istvan M, Schreck B, Mainguy M, Jolliet P, Grall-Bronnec M, Victorri-Vigneau C. Perception of the regulatory change for Zolpidem prescription by French general practitioners and its relation to prescription behavior. J Clin Med. 2022;11(8):2176.
Article PubMed PubMed Central Google Scholar
Food and Drug Administration Drug Safety Communication. Risk of next-day impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edular, and Zolpimist). UCM 335007. January 10, 2013 Research
Greenblatt DJ, Harmatz JS, Roth T. Zolpidem and gender: are women really at risk? J Clin Psychopharmacol. 2019;39(3):189–99.
Article CAS PubMed Google Scholar
Burke JP, Jain A, Yang W, Kelly JP, Kaiser M, Becker L, Lawer L, Newschaffer CJ. Does a claims diagnosis of autism mean a true case? Autism. 2014;18(3):321–30.
Spettell CM, Wall TC, Allison J, Calhoun J, Kobylinski R, Fargason R, Kiefe CI. Identifying physician-recognized depression from administrative data: consequences for quality measurement. Health Serv Res. 2003;38(4):1081–102.
留言 (0)